Reviews/Targeted Therapy Prostate Cancer/Enzalutamide or darolutamide overall survival in metastatic hormone-sensitive prostate cancer
Adt Intensify · PC-ADT-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
This claim bundles three trials together and says adding either enzalutamide or darolutamide to hormone therapy plus the chemotherapy docetaxel helps men with advanced prostate cancer live longer. Only one of the three trials actually tested that exact combination: ARASENS gave darolutamide on top of hormone therapy and docetaxel, and found a clear survival benefit [1][3]. The other two trials did something different: ARCHES added enzalutamide to hormone therapy with no chemotherapy backbone [2][7], and ENZAMET compared enzalutamide against an older anti-androgen drug with chemotherapy left to the doctor's choice [6][10]. A separate analysis of the ENZAMET data even suggested that adding docetaxel to enzalutamide did not improve survival [5]. So the darolutamide part of the claim is well supported, but attributing the same triplet survival benefit to enzalutamide and to the ARCHES and ENZAMET trials goes beyond what those studies tested.
ARASENS is the only randomized trial in the corpus that tested the exact combination the claim describes, randomizing darolutamide versus placebo with both arms on androgen-deprivation therapy plus docetaxel, and reporting a significantly lower risk of death (hazard ratio 0.68; 95% CI, 0.57 to 0.80; P<0.001) [1], with benefit consistent across disease-volume and risk subgroups [3]. ARCHES randomized enzalutamide plus ADT versus placebo plus ADT with no docetaxel backbone (HR 0.66; 95% CI, 0.53 to 0.81) [2][7], and ENZAMET compared enzalutamide against a non-steroidal antiandrogen with docetaxel left to physician choice (HR 0.67; 95% CI, 0.52 to 0.86) [6][10]. A target-trial emulation of ENZAMET found that adding early docetaxel to enzalutamide did not improve survival (HR 1.18; 95% CI, 0.94 to 1.49) [5]. Real-world triplet data are mixed: one TriNetX analysis favored the darolutamide triplet over an ARPI doublet (HR 0.601; 95% CI, 0.420 to 0.862) [21], while another cohort reported no clear difference in OS between doublet and triplet [20]. The contested point: The division is scope: whether the enzalutamide half of the claim is supported at all. ARCHES and ENZAMET did not use an ADT-plus-docetaxel backbone [2][6][7][10], and the one direct test of adding docetaxel to enzalutamide found no survival gain [5], so the claim's triplet attribution holds for darolutamide [1] but overreaches for enzalutamide.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim describes an ADT + docetaxel backbone (triplet) but cites ARCHES, which randomized enzalutamide + ADT vs placebo + ADT with no docetaxel backbone (only 18% had prior docetaxel) [2][7]. ARCHES does not test triplet therapy, so attributing a triplet OS benefit to it is a category error.
ENZAMET [6][10] compared enzalutamide against an NSAA active comparator with docetaxel left to physician choice, not a docetaxel backbone. The target-trial emulation of ENZAMET [5] found adding early docetaxel to enzalutamide did not improve OS (HR 1.18, 95% CI 0.94-1.49). There is therefore no evidence that enzalutamide added to ADT+docetaxel improves OS, and indirect evidence against it.
Where it remains uncertain. ARCHES added enzalutamide to ADT alone [2][7] and ENZAMET used an NSAA comparator with optional docetaxel [6][10], while an emulation found adding docetaxel to enzalutamide did not improve OS (HR 1.18; 95% CI, 0.94 to 1.49) [5].
Aleatory
OS estimates in smaller subgroups carry wide confidence intervals, e.g. the ARASENS low-volume subgroup (HR 0.68; 95% CI, 0.41 to 1.13) [3].
Epistemic
No trial in the corpus randomizes enzalutamide on an ADT-plus-docetaxel backbone, so the enzalutamide half of the claim has no direct randomized test [2][6][7][10].
Inferential
Real-world triplet cohorts are nonrandomized with short or unequal follow-up and differing comparators, limiting causal inference [16][20][21].
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary phase-3 RCT proof that darolutamide added to ADT + docetaxel significantly improves OS — the only true triplet trial for the claim
“the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001)”
Panel auditInternal validity: high · scope of inference: Patients with metastatic hormone-sensitive prostate cancer eligible for ADT plus docetaxel; 86.1% metastatic at initial diagnosis.Key limitations: industry funded (Bayer/Orion) · single primary analysis cutoff · docetaxel-eligible population only
Shows enzalutamide improves OS, but on an ADT (not ADT+docetaxel) backbone — relevant yet indirect to the triplet wording
“Enzalutamide plus ADT reduced risk of death by 34% versus placebo plus ADT (median not reached in either group; hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P < .001)”
Panel auditInternal validity: high · scope of inference: mHSPC patients on ADT; docetaxel was a stratification factor (prior docetaxel), not a universal backbone, so this does not isolate the triplet.Key limitations: 31.3% placebo crossover may dilute OS · comparator is ADT not ADT+docetaxel · industry context
Confirms the darolutamide triplet OS benefit is robust across disease-volume and risk subgroups
“Darolutamide increased overall survival (OS) versus placebo in patients with high-volume (hazard ratio [HR], 0.69; 95% CI, 0.57 to 0.82), high-risk (HR, 0.71; 95% CI, 0.58 to 0.86), and low-risk disease (HR, 0.62; 95% CI, 0.42 to 0.90)”
Panel auditInternal validity: high · scope of inference: mHSPC patients on ADT plus docetaxel, stratified by disease volume and risk.Key limitations: subgroup analysis (reduced power) · low-volume subgroup not significant · industry funded
Directly qualifies the claim: adding docetaxel to enzalutamide did not improve OS, so the enzalutamide-triplet reading is not supported
“Among those assigned enzalutamide, OS was similar according to the planned use of early docetaxel or not (HR 1.18, 95% CI 0.94-1.49), regardless of disease volume”
Panel auditInternal validity: medium · scope of inference: ENZAMET mHSPC population, effect of adding early docetaxel to enzalutamide.Key limitations: non-randomised emulation · selection bias/residual confounding · docetaxel not randomly assigned
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong primary-RCT support for the darolutamide triplet leg is offset by a material scope overreach on the enzalutamide and ARCHES/ENZAMET attributions, which are not triplet trials and are partly contradicted by the corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomized enzalutamide triplet trial. The claim attributes a triplet OS benefit to enzalutamide, but every enzalutamide trial in the corpus used a non-docetaxel backbone [2][7] or an NSAA comparator with optional docetaxel [6][10]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized trial of enzalutamide versus placebo, both on ADT plus docetaxel, with overall survival as the primary endpoint.
Open question: Does adding enzalutamide to ADT plus docetaxel improve overall survival relative to ADT plus docetaxel alone? Why it is still open: No randomized triplet trial of enzalutamide exists in the corpus, and the only direct test, an observational emulation, found no benefit (HR 1.18; 95% CI, 0.94 to 1.49) [5].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19